Skip to content

Aspen concludes exclusive European licensing agreement with Devintec Pharma for a patented women’s health medical device 

Dublin, Ireland – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmacare Holdings Limited, a JSE-listed global multinational specialty pharmaceutical company, has concluded an exclusive licensing agreement (“Agreement”) with Swiss-based Devintec Pharma (“Devintec”) for Europe. 

The Agreement is for a unique patented European Union-registered Medical Device Class II for the treatment of vaginal infections and the recurrence thereof. 

Daniel Vella Friggieri, Aspen Regional CEO Europe & Middle East, said, “This agreement strengthens Aspen’s ongoing commitment to innovation in all markets, including the Europe & Middle East region. We look forward to further strengthening our offering in Women’s Healthcare when the product launches during H2 FY25 by providing women with a unique, clinically tested option with naturally functioning ingredients.” 

Rossana Sidoti, General Manager at Devintec Pharma, commented, “We are excited to partner with Aspen to launch their branded version of Ginenov. Aspen’s expertise in gynecology, combined with their distribution network, offers exciting prospects of reaching more female patients, enhancing their quality of life and strengthening our position in women’s health.” 

Download the Press Release

Issued by: Firas Nabulsi, Aspen Europe & Middle East Head of Business Development and Marketing 

Tel: +971 4 363 4932 | 

On behalf of: Daniel Vella Friggieri, Aspen Europe & Middle East Regional CEO 

Tel: +971 4 363 4925 | 

About Aspen 

Headquartered in Durban, South Africa, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. Aspen employs more than 9 100 employees at 65 established offices in over 50 countries and territories. 

Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and regional brands covering both hospital and consumer markets. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising injectable products, prescription and OTC medicines. 

Aspen improves the health of patients around the world through its high quality, affordable and effective healthcare solutions. The Group operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. The Group’s manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. 

For more information visit 

About Devintec Pharma

Devintec Pharma is a private company based in Lugano, Switzerland. Devintec Pharma’s business is based on advanced Research & Development that leads to discovering, developing, and successively licensing innovative substance-based medical devices. 

Devintec Pharma’s mission is clear: focusing on creating treatments that get to the root of the problem and restore natural permeability. Devintec Pharma follows the motto that “every patient has his own story, so it looks to offer a range of clinically proven solutions that answer each specific need.” 

Devintec Pharma applies the unique technology of DevinPro™ to its patented healthcare solutions. This innovative mechanism of action forms a protective mucus-like barrier that avoids the adhesion and proliferation of pathogens and promotes epithelial integrity, enabling the treatment of multiple diseases and providing clinically proven, non-pharmaceutical solutions with a strong safety and efficacy profile. 

For more information visit

Scroll To Top